Literature DB >> 20923924

A systematic review of hypothalamic-pituitary-adrenal axis function in schizophrenia: implications for mortality.

Andrew J Bradley1, Timothy G Dinan.   

Abstract

There is convincing evidence that environmental stress plays a significant role in modifying both mental and physical health. The biological mechanisms linking stress to ill health are not fully understood, but significant evidence points to a central role of the stress axes; the hypothalamic- pituitary-adrenal (HPA) axis and the sympathetic nervous system. Together these two systems link the brain and the body and are crucial in maintaining homeostasis as well as improving an organism's survival chances in the face of environmental challenge. There is evidence of altered HPA axis function in people with a range of mental disorders, and this may in part explain the poor physical health of people with psychotic, mood and anxiety disorders. This paper systematically reviews HPA axis function in people with schizophrenia and relates this to the pattern of physical health seen in this disease. In summary, the evidence suggests people with schizophrenia can experience both hyper- and hypo-function of the HPA axis. It is likely that this contributes to the pattern of poor physical health and premature mortality suffered by people with schizophrenia, in particular the high rates of cardiovascular and metabolic disturbance.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20923924     DOI: 10.1177/1359786810385491

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  66 in total

1.  Plasma cortisol in first episode drug-naïve mania: differential levels in euphoric versus irritable mood.

Authors:  Leandro L Valiengo; Márcio G Soeiro-de-Souza; Andrea H Marques; Doris H Moreno; Mário F Juruena; Ana Cristina Andreazza; Wagner F Gattaz; Rodrigo Machado-Vieira
Journal:  J Affect Disord       Date:  2012-02-02       Impact factor: 4.839

2.  Respiratory, metabolic and cardiac functions are altered by disinhibition of subregions of the medial prefrontal cortex.

Authors:  Sarah F Hassan; Jennifer L Cornish; Ann K Goodchild
Journal:  J Physiol       Date:  2013-09-16       Impact factor: 5.182

3.  Insomnia and suicidal ideation in nonaffective psychosis.

Authors:  Brian J Miller; Carmen B Parker; Mark H Rapaport; Peter F Buckley; William V McCall
Journal:  Sleep       Date:  2019-02-01       Impact factor: 5.849

4.  Abnormal glucocorticoid receptor mRNA and protein isoform expression in the prefrontal cortex in psychiatric illness.

Authors:  Duncan Sinclair; Shan Yuan Tsai; Heng Giap Woon; Cynthia Shannon Weickert
Journal:  Neuropsychopharmacology       Date:  2011-08-31       Impact factor: 7.853

5.  Medical Co-morbidities Among Patients with Severe Mental Illnesses in a Community Health Facility in Nigeria.

Authors:  Victor Olufolahan Lasebikan; Joachim Azegbeobor
Journal:  Community Ment Health J       Date:  2016-11-25

6.  Do child abuse and maltreatment increase risk of schizophrenia?

Authors:  Lucia Sideli; Alice Mule; Daniele La Barbera; Robin M Murray
Journal:  Psychiatry Investig       Date:  2012-04-30       Impact factor: 2.505

Review 7.  Bridging Autism Spectrum Disorders and Schizophrenia through inflammation and biomarkers - pre-clinical and clinical investigations.

Authors:  Joana Prata; Susana G Santos; Maria Inês Almeida; Rui Coelho; Mário A Barbosa
Journal:  J Neuroinflammation       Date:  2017-09-04       Impact factor: 8.322

8.  Pituitary volume in schizophrenia spectrum disorders.

Authors:  F Romo-Nava; W S Hoogenboom; P E Pelavin; J L Alvarado; L H Bobrow; F P Macmaster; M Keshavan; R W McCarley; M E Shenton
Journal:  Schizophr Res       Date:  2013-03-19       Impact factor: 4.939

Review 9.  Are there modifiable risk factors which will reduce the excess mortality in schizophrenia?

Authors:  Hiram Joseph Wildgust; Mike Beary
Journal:  J Psychopharmacol       Date:  2010-11       Impact factor: 4.153

Review 10.  Brain circuit dysfunction in a distinct subset of chronic psychotic patients.

Authors:  Morris B Goldman
Journal:  Schizophr Res       Date:  2014-07-01       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.